September 4, 2003

Skinvisible's OPS Rating of '8'Reiterated by StockDiagnostics.com

StockDiagnostics.com announced that it has reiterated its OPS Rating of '8'for Skinvisible, Inc. (OTC:SKVI). Skinvisible has had an OPS Rating of '8'for fourteen consecutive quarters.

StockDiagnostics.com's maintaining of the OPS RatingTM is based on Skinvisible's recently filed Cash Flow Statements for its quarter ended June 30, 2003. The company's computed OPS TM (Operational-cashflow Per Share) for the quarter was $-0.004 per share as compared to $-0.01 per share for the comparable year earlier quarter. OPS for the most recent 12 months ended June 30, 2003 was $-0.02 per share as compared to $-0.03 per share for the 12 months ended June 30, 2002. OPS for Skinvisible's trailing twelve months reached a three year high.

The shares of Skinvisible were recently trading at $0.14.

About OPS RatingsTM -- StockDiagnostics.com monitors Operational cash flow Per Share ('OPS') for over 7,000 publicly traded companies and assigns them an 'OPS Rating', which measures the long term risk associated with a company's ability to remain in business. A company's 'OPS'logically falls into a mathematical sequence that ranks it into one of eight distinctive 'risk'categories. Each of the categories is based on a company's operating cash flow for each of its last 4 quarters and its cumulative operating cash flow for its most recent 12 months. OPS Ratings are upgraded, downgraded or reiterated each time a company files a quarterly report and at any time that its financial statements are amended. Statistical research on OPS Ratings is available at http://www.StockDiagnostics.com/marketnews.

About StockDiagnostics.com -- StockDiagnostics.com monitors 1,801 data points on over 10,000 publicly traded companies. It has a proprietary data refinery that automates the process of collecting, sorting and organizing large amounts of securities pricing and financial data into comparative financial ratios. These ratios are used to identify Financial Statement anomalies and securities pricing variances to monitor changes in the performance of public companies. Go to http://www.StockDiagnostics.com/marketnews for a description of StockDiagnostics.com's patent-pending technical applications, such as OPS, OPS Ratings, The EPS Syndrome and more. Full details are available at http://www.StockDiagnostics.com/marketnews.

Press Release Index

New Press Release Alerts:

If you are interested in receiving corporate and new product development news from Skinvisible, simply enter your email address below.